Nature Communications · 2022 · 45 citations · 29 references
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryDrug DiscoveryControlled Release MechanismsDrug EncapsulationNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignAdherenceHiv Transmission ReductionHydrolysisHydrolytic Prodrug ReleaseIntegrase ProteinsNanocarrier-based ProdrugsPharmacokinetics Of NanocarriersProdrug Release Mechanisms
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18-carbon chain modified ester prodrug nanocrystal (coined NM2DTG) with the potential to sustain yearly dosing. Here, we show that the physiochemical and pharmacokinetic (PK) formulation properties facilitate slow drug release from tissue macrophage depot stores at the muscle injection site and adjacent lymphoid tissues following single parenteral injection. Significant plasma drug levels are recorded up to a year following injection. Tissue sites for prodrug hydrolysis are dependent on nanocrystal dissolution and prodrug release, drug-depot volume, perfusion, and cell-tissue pH. Each affect an extended NM2DTG apparent half-life recorded by PK parameters. The NM2DTG product can impact therapeutic adherence, tolerability, and access of a widely used integrase inhibitor in both resource limited and rich settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.
29
David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 504 citations
Adverse effects of antiretroviral therapy for HIV infection.
Valentina Montessori, Natasha Press, Marianne Harris et al. · PubMed · 2004 · 361 citations · Full text
Best Practices Guideline: Toxicologic Histopathology
James W. Crissman, Dawn G. Goodman, Paul K. Hildebrandt et al. · Toxicologic Pathology · 2004 · 343 citations · Full text
Pharmacy, Pathology, Toxicology +14